(TheNewswire)
Edmonton, 18 June 2024 – TheNewswire – Innovotech Inc. (TSX-V: IOT) reports the publication of“Antiviral Activity of Ag 5 IO 6 , A UniqueSilver Compound” in the Special Issue of Viruses entitled“Impact of Co-Infections in COVID-19: Predisposing Mechanisms andInterplay between Invasive Viral, Bacterial, and Fungal Pathogens”( Viruses 2024, 16(6), 959, https://doi.org/10.3390/v16060959 ).
The reported study shows that Innovotech’sInnovoSIL™-1 silver periodate, originally developed for itsbroad-spectrum antimicrobial activity, including antibiofilm activity,has demonstrated rapid virucidal activity against norovirus and twostrains of the SARS-CoV-2 virus.
In vitro testing following ASTM E1052-20 (Standard Practice to Assess theActivity of Microbicides Against Viruses in Suspension), showed thatInnovoSIL™-1 silver was able to generate total kill of the omicronstrain of COVID-19 within 30 minutes, as well as total kill of murinenorovirus and the original COVID-19 strain within four hours.
Based on its performance in this study, it isanticipated that InnovoSIL™-1 silver would also be effective againstviruses such as influenzas, herpes simplex virus 1 (HSV-1), andrespiratory syncytial viruses (RSVs). The study showed low activityagainst adenovirus and no measurable antiviral activity againstpoliovirus.
InnovoSIL™-1 silver’s antiviral properties arebroadly efficacious in wound dressings and medical devices, as well asnew potential applications, such as coatings on touch surfaces orincorporation into air filters. In addition, these propertiesuniquely position InnovoSIL™-1 silver for situations where eitherinfection prevention or simultaneous treatment of microbes (bacteriaor fungi) and viruses are desirable.
Innovotech would like to acknowledge AlbertaInnovates’ support for this research through an AICE-Validatesgrant.
About InnovoSIL™-1 AntimicrobialSilver
InnovoSIL™-1 antimicrobial silver possessesexceptional properties for efficacy against microbial biofilms, aswell as long-term broad spectrum anti-adherence activity. It is simpleto coat onto or incorporate into medical devices, with favorablerelease characteristics. Its unique structure limits its inactivationby bodily fluids. Combining silver and iodine increases itsantimicrobial mechanisms of action, reducing the likelihood of atarget developing resistance to it. InnovoSIL™-1 antimicrobialsilver has demonstrated excellent stability under a wide variety ofconditions and can be easily synthesized with high purity in a formthat is simple to deposit onto metals or incorporate into wounddressings, gels, or polymers. Innovotech is presently working with anumber of industry collaborators who are pursuing a variety ofapplications for InnovoSIL™-1 antimicrobial silver.
About Innovotech Inc:
Innovotech is a Canadian biotechnology company owningproprietary intellectual property, conducting contract research, andowning and providing proprietary devices for testing in multipleapplications in microbiology and can be found online at www.innovotech.ca .
Patricia Nadworny, Ph.D., B.Sc.,P.Eng.
Chief Scientific Officer Innovotech Inc.
+780-448-0585x7 partricia.nadworny@innovotech.ca
This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the valueof the Canadian dollar; the Company’s reliance on a small number of customersincluding government organizations; fluctuations in operating results;government policies or actions; progress and cost of clinical trials;reliance on key strategic relationships; uncertainty related tointellectual property protection and potential costs associated withits defense; the Company’s exposure to lawsuits and other mattersbeyond the control of management. Should known or unknown risks oruncertainties materialize, or should management’s assumptions proveinaccurate, actual results could vary materially from thoseanticipated. The Company undertakes no obligation to publicly make orupdate any forward- looking statements, except as required byapplicable law.
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this release.
###
Copyright (c) 2024 TheNewswire - All rights reserved.